Department of Surgery, Taichung Hospital, Ministry of Health and Welfare, Taichung, Taiwan.
Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.
J Wound Care. 2021 Sep 2;30(Sup9a):IXi-IXxi. doi: 10.12968/jowc.2021.30.Sup9a.IX.
Chitosan and epidermal growth factor (EGF) have been shown to improve wound healing. This study investigates the healing effects of a spray solution (NewEpi, JoyCom Bio-Chem Co. Ltd., Taiwan) containing recombinant human EGF (rhEGF) delivered via a newly patented technology-chitosan microencapsulated nanoparticles.
On Wistar rats, two full-thickness wounds on the dorsum bilateral of the spine were created. The rats were randomised to the following treatment groups: hydrogel, wet dressing, foam, rhEGF spray and rhEGF spray+foam. Sterile dressings were applied and changed daily. A total of 2μg of rhEGF was administered in two sprays during each dressing change. All animals were euthanised on day 14. Tissue samples were taken from the wound bed, including an area of 2cm surrounding the wound margin for histological evaluations.
Wounds treated with the rhEGF spray achieved the greatest size reduction by day 14 compared with other types of conventional dressings. An overall significant difference in levels of collagen synthesis existed between groups (p<0.01). Pair-wise comparisons showed that the rhEGF spray treatment significantly promoted higher levels of mature Type I collagen than any other conventional dressings (p<0.01), whereas non-rhEGF treatments resulted in higher levels of Type III collagen. The regenerated tissue in rhEGF spray treatment groups was also in alignment with that of normal skin. Epidermis, dermis and hair follicles were easily observed in wounds treated with the rhEGF spray.
The major challenge of topical application of rhEGF was overcome by using a new drug delivery technology: chitosan-rhEGF nanoparticles. The positive healing effects observed in this study suggest the therapeutic potentials of this novel rhEGF topical spray solution.
壳聚糖和表皮生长因子（EGF）已被证明可促进伤口愈合。本研究旨在探讨一种新型专利技术（壳聚糖微囊化纳米粒）递送的含重组人 EGF（rhEGF）的喷雾溶液（NewEpi，JoyCom Bio-Chem Co. Ltd.，中国台湾）的愈合效果。
在 Wistar 大鼠背部脊柱两侧的两个全层伤口上进行实验。将大鼠随机分为以下治疗组：水凝胶组、湿性敷料组、泡沫组、rhEGF 喷雾组和 rhEGF 喷雾+泡沫组。每天使用无菌敷料进行处理和更换。每次更换敷料时，共给予 2μg rhEGF 进行两次喷雾。所有动物均于第 14 天处死。从伤口床中采集组织样本，包括伤口边缘周围 2cm 的区域进行组织学评估。
rhEGF 喷雾组在第 14 天的伤口面积缩小程度最大，与其他类型的常规敷料相比。各组之间胶原合成水平存在显著差异（p<0.01）。两两比较表明，rhEGF 喷雾治疗显著促进了比任何其他常规敷料更高水平的成熟 I 型胶原（p<0.01），而无 rhEGF 的治疗则导致更高水平的 III 型胶原。rhEGF 喷雾治疗组的再生组织也与正常皮肤一致。rhEGF 喷雾处理的伤口中很容易观察到表皮、真皮和毛囊。
通过使用新的药物递送技术克服了 rhEGF 局部应用的主要挑战：壳聚糖-rhEGF 纳米粒。本研究观察到的积极愈合效果表明这种新型 rhEGF 局部喷雾溶液具有治疗潜力。
